Provided by Integrity Continuing Education, Inc. and Tumor Board Tuesday.
Supported by educational grants from Astellas; Astrazeneca Pharmaceuticals; Exelixis; Gilead Sciences, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck Sharp & Dohme Corp; and Seagen.
Michael J. Pishvaian, MD, PhD
Associate Professor, Department of Oncology
Director of the Gastrointestinal, Development Therapeutics, and Clinical Research Programs at the NCR
Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, District of Columbia
Johnathan Ebben, MD, PhD
Division of Hematology, Oncology, and Palliative Care
University of Wisconsin-Madison
#TumorBoardTuesday takes place on Tuesdays at 8 PM Eastern Time. You can join the conversation at https://twitter.com/TumorBoardTues
|Tuesday, October 24, 2023||New Options in Mesothelioma|
|Patrick Forde, MB, BCh|
Co-Director, Division of Upper Aerogestive Malignancies
Director, Thoracic Oncology Research Program
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University
Sarah Lochrin, MB, BCh
Advanced Fellow in Medical Oncology
Memorial Sloan Kettering Cancer Center
|Patrick Forde, MB, BCh|
Consultant: Amgen, Ascendis, AstraZeneca, Bristol Myers Squibb, Curevac, Flame, Fosun, F Star, G1, Genelux, Genentech, Gritstone, Iteos, Janssen, Merck, Novartis, Regeneron, Sanofi, Synthekine, Tavotek, Teva.
Research: AstraZeneca, BioNTech, Bristol Myers Squibb, Novartis, Regeneron
Sarah Lochrin, MB, BCh has no real or apparent conflicts to disclose.
|Tuesday, September 5, 2023||IO Perioperative Therapy NSCLC|
|Narjust Florez, MD|
Associate Director of Cancer Care Equity
Dana-Farber Cancer Institute
Harvard Medical School
Shruti Rajesh Patel, MD
Department of Oncology
Stanford Health Care
|Narjust Florez, MD has no real or apparent conflicts to disclose.|
Shruti Rajesh Patel, MD has no real or apparent conflicts to disclose.
|Tuesday, August 8, 2023||TX After Progression on Osimertinib|
|Melina Marmarelis, MD, MSCE|
Assistant Professor of Medicine
University of Pennsylvania
Eleanor Taranto, MD
Hematology and Oncology Fellow
Hospital of the University of Pennsylvania
|Melina Marmarelis, MD, MSCE|
Consultant: AstraZeneca, Janssen, Ikena, Boehringer Ingelheim, Takeda, Novocure, Blueprint Pharmaceuticals, BMS
Stock: Gilead Sciences & Portola Pharmaceuticals, Merck, Bluebird Bio, Johnson & Johnson, Pfizer
Research Funding (To Institution): AstraZeneca, Eli Lilly, Merck, Genentech
Honorarium: Thermo Fisher
Eleanor Taranto, MD has no real or apparent conflicts to disclose
|Tuesday, April 25, 2023||Exon 20ins TX NSCLC|
|Ticiana Leal, MD|
Associate Professor, Director Thoracic Medical Oncology Program
Winship Cancer Institute Emory University
Jennifer Carlisle, MD
Winship Cancer Institute
|Ticiana Leal, MD has no real or apparent conflicts to disclose|
Jennifer Carlisle, MD has no real or apparent conflicts to disclose
Stay tuned for upcoming conversations!
Oncologists and other clinicians who treat patients with lung cancers have generally adopted molecular profiling technologies offering insight into the molecular underpinning of thoracic based tumors. Considering the challenges of managing these tumor types, understanding these molecular alterations is critical to incorporating newly approved and emerging targeted agents, including immunotherapies. Yet, translating these findings into clinical applications can be challenging. Determining which potential biomarkers and/or druggable mutations in lung cancer that benefit patients is instrumental in improving patient outcomes. Oncologists need greater understanding and insight into the foundational genomic discoveries that underly the use of targeted entities.
Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.
This activity is designed to meet the needs of medical, surgical and radiation oncologists, physician assistants, nurse practitioners, nurses and other healthcare providers involved in treatment and management of patients with lung cancer.
Upon completion of this educational activity, participants will be able to:
There are no fees for participating and receiving CME credit for this activity. During the certification period, participants must:
If you wish to claim credit for your participation in TBT conversations from March 21, 2023 – Present you can do so here: www.integrityce.com/TBTeval23
Physician Continuing Education
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this live material for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or firstname.lastname@example.org.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
Michael L. Pishvaian, MD, PhD
Ad Hoc Advisory Boards: AstraZeneca, Ideaya, Merck, Merus, Seattle Genetics
Educational (Unbranded) Program Speaker: Novartis, Pfizer
Steering Committee: Astellas, Pionyr, Trisalus
Funding to Institution: Amgen, Arcus Bio, Biomed Valley, Boerhinger Ingelheim, Ideaya, Seattle Genetics, Merck, Novartis, Pfizer, RenovoRx, Repare Tx, Tesaro, Tizonia
Stock Ownership: Perthera, Inc.
Johnathan Ebben, MD, PhD
Other (CEO): NanoRED
The Integrity Continuing Education, Inc. planners and managers and Tumor Board Tuesday patient planner do not have any financial relationships or relationships to products or devices with ineligible companies.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.